01948nas a2200397 4500000000100000008004100001260000900042653001000051653000900061653001200070653002800082653001100110653003800121653001300159653002800172653001100200653001200211653000900223653001600232653003600248653001700284100001200301700001500313700001300328700001400341700001300355700001100368700002500379245010100404856007900505300001100584490000600595050001500601520092000616022001401536 2012 d c2012 10 aAdult 10 aAged 10 aAlleles 10 aCytochrome P-450 CYP2E1 10 aFemale 10 aGenetic Predisposition to Disease 10 agenotype 10 aGlutathione Transferase 10 aHumans 10 aleprosy 10 aMale 10 aMiddle Aged 10 aPolymorphism, Single Nucleotide 10 aRisk Factors 1 aPinto P 1 aSalgado CG 1 aSantos N 1 aAlencar D 1 aSantos S 1 aHutz M 1 aRibeiro-Dos-Santos A 00 aPolymorphisms in the CYP2E1 and GSTM1 genes as possible protection factors for leprosy patients. uhttp://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0047498 ae47498 0 v7 aPINTO 2012 3 aBACKGROUND: The CYP2E1 and GSTM1 genes encode metabolic enzymes that have key functions in drug modification and elimination.
METHODOLOGY/PRINCIPAL FINDINGS: We investigated the possible effects of CYP2E1 and GSTM1 polymorphisms in 71 leprosy patients and in 110 individuals from the general population. The GSTM1*0 null allele and INDEL CYP2E1*1D mutant genotypes were analyzed by conventional PCR, while CYP2E1 SNPs (1053C>T, 1293G>C and 7632T>A) were determined by RT-PCR. In leprosy patients, the GSTM1*0 and CYP2E1*5 alleles and the combined alleles GSTM1*0/CYP2E1*6 and GSTM1*0/CYP2E1*5 were significantly related to a baciloscopic index (BI) (BI<3), while the CYP2E1*6 allele was related to a better clinical evolution in the leprosy spectrum.
CONCLUSIONS/SIGNIFICANCE: Therefore, GSTM1*0, CYP2E1*5 and CYP2E1*6 may be possible protection factors for leprosy patients.
a1932-6203